S
CRVS icon

SignatureFD’s Corvus Pharmaceuticals CRVS Stock Holding History

SignatureFD’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.99K Buy
136
+60
+79% +$958 ﹤0.01% 3059
2025
Q4 		$585 Hold
76
– – ﹤0.01% 3211
2025
Q3 		$560 Buy
+76
New +$389 ﹤0.01% 3175
2025
Q1 		– Sell
-224
Closed -$1.2K – 3344
2024
Q4 		$1.2K Buy
+224
New +$1.67K ﹤0.01% 2992

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SignatureFD's CRVS Position: Q1 2026 in Review

SignatureFD increased its Corvus Pharmaceuticals (CRVS) stake by 79% in Q1 2026, buying an estimated $958 and bringing the position to 136 shares worth $1.99K. The position accounts for ﹤0.01% of the portfolio, ranked #3059.

SignatureFD first reported a position in CRVS in Q4 2024 and has held it in 4 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • SignatureFD held 136 shares of Corvus Pharmaceuticals worth $1.99K as of Q1 2026.
  • SignatureFD bought 60 Corvus Pharmaceuticals shares in Q1 2026, an estimated $958.
  • Corvus Pharmaceuticals made up ﹤0.01% of SignatureFD's portfolio in Q1 2026, its #3059 holding.
  • SignatureFD first reported a position in Corvus Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.